Loading stock data…
ASRT
$22.36-0.14 (-0.62%)
Market ClosedLast close May 11
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Assertio Holdings, Inc. in the Healthcare sector is trading at $22.36. The stock is currently near its 52-week high of $22.58, remaining 71.9% above its 200-day moving average. Technical signals show overbought RSI of 97 and bullish MACD crossover, explaining why ASRT maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 97) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$22.36
Potential Upside
5%
Whystock Fair Value$23.48
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Buy
Mean target$23.87+6.7%
Range$21.80 – $28.00
Fundamentals
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$116.32M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.43
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-32.33%
Volume
Today's trading volume
264,148
Recent News
Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last?
Assertio (ASRT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
How The Assertio Holdings (ASRT) Story Is Shifting With The Garda Takeover And Valuation Anchor
The modelled fair value for Assertio Holdings sits at US$21.33 per share, with no adjustment to the central price target in the latest update. This stable target reflects how recent analyst commentary has shifted toward weighing risk and upside around the takeover agreement, rather than chasing higher headline numbers. As you read on, you will see how this steady US$21.33 anchor fits into the evolving story and what to watch if you are tracking Assertio’s next moves. Analyst Price Targets...
Are Medical Stocks Lagging Assertio (ASRT) This Year?
Here is how Assertio (ASRT) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.
How The Assertio Holdings (ASRT) Story Is Shifting With The Takeover And Reset Valuation
Assertio Holdings is back in focus after its fair value estimate was reset from US$37.44 to US$21.33, a cut of roughly 43% that reflects a more cautious stance on the stock. Analysts are weighing this price target change against the takeover agreement, with some seeing reduced standalone uncertainty, while others highlight capped upside and integration risk. Read on to see how to interpret these shifts and keep up with the evolving narrative around Assertio. Analyst Price Targets don't always...
Does Assertio (ASRT) Have the Potential to Rally 115.05% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 115.1% in Assertio (ASRT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.